论文部分内容阅读
目的研究绝经后骨质疏松(postmenopausal osteoporosis,POP)女性外周血中硬化蛋白(sclerostin,SOST)基因和核因子-κB受体活化因子配体(receptor activator of NF-κB ligand,RANKL)的表达水平,并探讨SOST和RANKL联合在POP患者中的检测价值。方法收集作者医院2015-04/2015-10月绝经后女性120名,分别进行骨密度(bone minaral density,BMD)和外周血清中SOST、RANKL以及雌二醇(estradiol,E_2)、孕酮(progesterone,P)水平检测,根据骨密度值分为POP组(n=42)和正常组(n=78)。结果 POP组中SOST、RANKL的水平高于正常组,而E2和P的水平低于正常组,差异均具有统计学意义(P<0.05);联合检测SOST和RANKL,预测POP的敏感性和特异性可以达到85.71%和88.46%。结论 SOST联合RANKL,E2以及P的检测可以提高绝经后骨质疏松症的检出率。
Objective To investigate the expression of sclerostin (SOST) and receptor activator of NF-κB ligand (RANKL) in postmenopausal osteoporosis (POP) , And explore the combined detection of SOST and RANKL in patients with POP. Methods Totally 120 postmenopausal women were collected from the hospital from April 2015 to October 2015. The bone mineral density (BMD) and the serum levels of SOST, RANKL, estradiol (E2) and progesterone , P) were measured and divided into POP group (n = 42) and normal group (n = 78) according to the BMD. Results The levels of SOST and RANKL in POP group were higher than those in normal group, while the levels of E2 and P in POP group were lower than those in normal group (P <0.05). The combined detection of SOST and RANKL predicted the sensitivity and specificity of POP Sex can reach 85.71% and 88.46%. Conclusion SOST combined with RANKL, E2 and P can improve the detection rate of postmenopausal osteoporosis.